Russell Z. Szmulewitz to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.920
-
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
Score: 0.237
-
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539.
Score: 0.104
-
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 08; 9(8).
Score: 0.099
-
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050.
Score: 0.092
-
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 11; 79(15):1752-1761.
Score: 0.087
-
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986.
Score: 0.086
-
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 09; 24(9):1151-e817.
Score: 0.085
-
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate. 2017 03; 77(4):385-395.
Score: 0.071
-
Corticosteroids and prostate cancer: friend or foe? Eur Urol. 2015 May; 67(5):874-5.
Score: 0.061